Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Revise PMD Law to Create Emergency Approval System, Final Paper Due Out by Year-End
December 23, 2021
- Chuikyo OKs FY2022 Drug Pricing Reform Outline; Spillover Exclusion, Mega Seller Rule
December 23, 2021
- Japan Seeks Additional Study for Aducanumab, Next Review Might Be Few Years Off
December 23, 2021
- Japan to Cut Drug Prices by 1.35% on Medical Cost Basis; No Special Rule for Adjustment Rate This Time
December 22, 2021
- AZ’s COVID-19 Drug to Be Reviewed with Priority if Filed in Japan: Senior Vice Minister
December 22, 2021
- Gist of FY2022 Drug Pricing Reform
December 22, 2021
- Look into Relationship Between COVID-19 Vaccination and Adverse Events: MHLW Panel
December 22, 2021
- Mochida’s Inhaled Treprostinil Gets Orphan Status
December 22, 2021
- Japan Expected to Cut Drug, Medical Device Prices by 160 Billion Yen on National Offers Basis
December 21, 2021
- MHLW Panel OKs “Specific-Use” Drug Designation for Dexmedetomidine
December 21, 2021
- Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
- Noxafil Contraindicated for Combined Use with Lonasen, Belsomra
December 20, 2021
- PM Kishida Vows to Move Up Booster, Offer COVID-19 Pill as Japan Girds for Omicron
December 20, 2021
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
- LDP Study Group Proposal Calls for 2%-Plus Adjustment Rate for 2022 Drug Price Revision
December 16, 2021
- Chuikyo Backs MHLW Proposal on Fertility Treatment Coverage
December 16, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Japan to Boost Pharma Startup Ecosystem via VC Certification Program, Allocates 50 Billion Yen in FY2021 Extra Budget
December 15, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…